+44 20 8123 2220
info@marketpublishers.com

Gallbladder cancer - Pipeline Insight, 2021

https://marketpublishers.com/r/G9DE9073EF1EN.html
Date: February 2021
Pages: 60
Price: US$ 1,500.00 (Single User License)
ID: G9DE9073EF1EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Gallbladder cancer - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Gallbladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Gallbladder cancer Understanding

Gallbladder cancer: Overview

Gallbladder cancer is a small, pear shaped organ located beneath the liver. The bladder stores bile enzymes produced by the liver and helps in digestion. Gallbladder cancer is a rare type of cancer that is characterized by the abnormal growth of cells in the Gallbladder cancer area. Most of the Gallbladder cancer begins in glandular cells which form the lining of the inner surface of the organ. This type of cancer is very rare and is caused due to the DNA mutations in the Gallbladder cancer cells. Gallbladder cancer is more common in middle aged women with a history of gallstones. However, it can also occur in men. Gallbladder cancer can be of various types such as papillary adenocarcinomas, adenosquamous carcinoma, squamous cell carcinoma, and others.

+44 20 8123 2220
info@marketpublishers.com

“Gallbladder cancer - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gallbladder cancer pipeline landscape is provided which includes the disease overview and Gallbladder cancer treatment guidelines. The assessment part of the report embraces, in depth Gallbladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gallbladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gallbladder cancer.

Gallbladder cancer Emerging Drugs Chapters

This segment of the Gallbladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gallbladder cancer Emerging Drugs

Durvalumab: Celgne

Celgene’ new drug candidate, Durvalumab, is human immunoglobulin G1 kappa monoclonal antibody that is in development for the treatment of Gallbladder cancers. It inhibits the immune response by blocking the interaction of PD-L1 with PD 1 and CD80. The drug has demonstrated good efficacy and safety results in its phase I clinical trials.

ONC 201: Ohara Pharmaceuticals

Ohara Pharmaceutical’s “breakthrough” drug ONC 201 is a small orally administered molecule in development for the treatment of Gallbladder cancer. The drug inactivates the Akt/ERK signaling, leading to upregulation of the proapoptotic immune cytokine TRAIL.

Further product details are provided in the report……..

Gallbladder cancer: Therapeutic Assessment

This segment of the report provides insights about the different Gallbladder cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gallbladder cancer

There are approx. 10+ key companies which are developing the therapies for Gallbladder cancer. The companies which have their Gallbladder cancer drug candidates in the most advanced stage, i.e. phase II include, Celgene.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Route of Administration

Gallbladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

Intramuscular

Intravenous

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gallbladder cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gallbladder cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gallbladder cancer drugs.

Gallbladder cancer Report Insights

+44 20 8123 2220
info@marketpublishers.com

Gallbladder cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Gallbladder cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Gallbladder cancer drugs?

How many Gallbladder cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gallbladder cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gallbladder cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

+44 20 8123 2220
info@marketpublishers.com

What are the clinical studies going on for Gallbladder cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Celgene

MedImmune

Ohara Pharmaceuticals

Key Products

Durvalumab

Tremelimumab

ONC 201?

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Executive Summary
Gallbladder cancer: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Gallbladder cancer – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
  Gallbladder cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends
Gallbladder cancer Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
  Comparative Analysis
Durvalumab : Celgene
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
ONC 201: Ohara Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities

+44 20 8123 2220
info@marketpublishers.com

Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Gallbladder cancer Key Companies
Gallbladder cancer Key Products
Gallbladder cancer- Unmet Needs
Gallbladder cancer- Market Drivers and Barriers
Gallbladder cancer- Future Perspectives and Conclusion
Gallbladder cancer Analyst Views
Gallbladder cancer Key Companies
Appendix

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1 Total Products for Gallbladder cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Gallbladder cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Gallbladder cancer - Pipeline Insight, 2021
Product link: https://marketpublishers.com/r/G9DE9073EF1EN.html
Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G9DE9073EF1EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970